Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.
T GraierW SalmhoferC JonakW WegerC KölliB GruberP G SatorK PrillingerA MlynekM Schütz-BergmayrL RichterG RatzingerC PainsiS SelhoferN HäringK Wippel-SlupetzkyH SkvaraH TrattnerA TanewM InzingerR TatarskiC BangertC EllersdorferR LichemA Gruber-WackernagelA HoferF LegatE SchmiedbergerR StrohalB Lange-AsschenfeldtMatthias SchmuthI VujicW HoetzeneckerF TrautingerW SaxingerR MülleggerF QuehenbergerPeter WolfPublished in: The British journal of dermatology (2021)
The time-dependent availability of drugs should be considered when analysing and comparing drug survival. Previous biologic exposure significantly influences drug survival. Women are more likely to stop treatment.